Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1231)	7/15/2005 3:52:27 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CVTX Is another stock making a new 52wks. H today in spite of its larger loss on the 1st Q and the larger EL for 2005 of$5.90 vs. $4.90 in 2004 <g> It announced on Wednesday that it was starting a PII on patients with asthma with its CVT-6883,which is an A2B-adenosine receptor antagonist.It is given orally on 1xday dose. By blocking the A2B-AR it could prevent mast cell degranulation, which is supposed to trigger the bronchoconstriction associated not only with asthma, but also with some other cardiopulmonary processes. A PI of its oral CVT-6883 in 24 healthy controls, was well tolerated with no significant side effects. The stock has been up more than 5% today bigcharts.marketwatch.com Bernard